Skip Navigation
Menu
Ideas and Opinions |3 July 2007

The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points

Ching-Lung Lai, MD; Man-Fung Yuen, MD, PhD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From the University of Hong Kong, Hong Kong, China.

    Potential Financial Conflicts of Interest: Grants received: C.L. Lai (Bristol-Myers Squibb).

    Requests for Single Reprints: Ching-Lung Lai, MD, Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China; e-mail, hrmelcl@hkucc.hku.hk.

    Current Author Addresses: Drs. Lai and Yuen: University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.

×
FULL TEXT
Approximately 350 to 400 million people worldwide have chronic hepatitis B virus (HBV) infection, with roughly 1.25 million cases in the United States and 180 000 in Britain. More than 70% of all people with chronic HBV infection are Asian. Although white persons in the U.S. and British populations are usually infected in adolescence or adulthood (by means of sexual contact or sharing of intravenous needles), nearly every Asian person with this infection (whether born in or outside Asia) acquires it at birth from an infected mother or within 2 years of birth by means of close contact with infected relatives.
There are important differences between these 2 groups. Patients infected in adolescence or adulthood immediately enter an immune clearance phase; their disease is of short duration and tends to become quiescent after they seroconvert from hepatitis B e antigen (HBeAg) to antibodies against HBeAg (anti-HBe). Such patients have been termed “healthy” carriers (1). In contrast, patients infected early in life have a prolonged immune tolerance phase followed by a prolonged immune clearance phase before HBeAg seroconversion, and strong evidence indicates that their disease progresses after HBeAg seroconversion.
Guidelines for treatment and treatment end points from 3 regional liver associations (the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver) suggest that treatment should be initiated for patients who are HBeAg seropositive if their HBV DNA levels are 105...
FULL TEXT
PDF
Not Available
Citations
Citation

Lai C, Yuen M. The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. Ann Intern Med. 2007;147:58–61. doi: 10.7326/0003-4819-147-1-200707030-00010

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2007;147(1):58-61.

DOI: 10.7326/0003-4819-147-1-200707030-00010

©
2007 American College of Physicians
127 Citations

Related Articles
Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium
Annals of Internal Medicine; 132 (9): 723-731
Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Meta-Analysis
Annals of Internal Medicine; 119 (4): 312-323
Cost-effectiveness of Interferon-α2b Treatment for Hepatitis B e Antigen-Positive Chronic Hepatitis B
Annals of Internal Medicine; 122 (9): 664-675
Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis
Annals of Internal Medicine; 142 (10): 821-831
View MoreView Less

Journal Club
Review: Oral drugs for type 2 diabetes, alone or in combination, have different relative benefits and harms for surrogate endpoints
Annals of Internal Medicine; 155 (4): JC2-4
Review: Evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B
Annals of Internal Medicine; 150 (10): JC5-6
Review: Interferon and nucleoside/tide analogues reduce risk for hepatocellular cancer in patients with chronic hepatitis B
Annals of Internal Medicine; 150 (8): JC4-11
What kind of randomized trials do patients and clinicians need?
Annals of Internal Medicine; 150 (10): JC5-2
View MoreView Less

Related Point of Care
Hepatitis C Virus
Annals of Internal Medicine; 165 (5): ITC33-ITC48
View MoreView Less

Related Topics
Gastroenterology/Hepatology
Infectious Disease
Liver Disease
Viral Hepatitis

Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Viral Hepatitis.

PubMed Articles
Vaccination coverage in children with rheumatic diseases.
Clin Exp Rheumatol 2019.
Exploratory spatial analysis of HBV cases in Brazil between 2005 and 2017.
Rev Bras Epidemiol 2019;22Suppl 1(Suppl 1):e190007.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×